On the relationship between methylnicotinate-induced skin flush and fatty acids levels in acute psychosis

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 927-933

  Maclean, Roderick ^a   Ward, Pauline E ^b   Glen, Iain ^b   Roberts, Stewart J ^a   Ross, Brian M ^b  

^a NHS HIGHLAND   (United Kingdom)

^b UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Bipolar disorder; Lipids; Niacin; Schizophrenia

Indexed keywords

AMISULPRIDE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DROPERIDOL; FATTY ACID; FLUOXETINE; FLUPENTIXOL; LITHIUM; LORAZEPAM; MEMBRANE LIPID; NICOTINIC ACID METHYL ESTER; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TEMAZEPAM; THIORIDAZINE; VENLAFAXINE; ZUCLOPENTHIXOL;

ACUTE PSYCHOSIS; ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ERYTHEMA; ERYTHROCYTE; ESSENTIAL FATTY ACID DEFICIENCY; FEMALE; FLUSHING; HUMAN; HUMAN EXPERIMENT; MALE; VASODILATATION;

EID: 0141517163     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00152-0     Document Type: Article

References (42)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Association, Washington, DC.
2. Assies J., Lieverse R., Vreken P., Wanders R.J., Dingemans P.M., Linszen D.H. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol. Psychiatry. 49:2001;510-522.
3. Babin F., Sarda P., Limasset B., Descomps B., Rieu D., Mendy F., Crastes de Paulet A. Nervonic acid in red blood cell sphingomyelin in premature infants: an index of myelin maturation? Lipids. 28:1993;530-627.
4. Bates C., Horrobin D.F., Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr. Res. 6:1991;1-7.
5. Bourre J.M., Bonneil M., Chaudiere J., Clement M., Dumont O., Durand G., Lafont H., Nalbone G., Pascal G., Piciotti M. Structural and functional importance of dietary polyunsaturated fatty acids in the nervous system. Adv. Exp. Med. Biol. 318:1992;211-229.
6. Carlson S.E., Carver J.D., House S.G. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: a comparison of rat neural and red cell membrane phospholipids. Nutrition. 116:1986;718-725.
7. Carver J.D., Benford V.J., Han B., Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 56:2001;79-85.
8. Derogatis L.R., Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol. Med. 13:1983;595-605.
9. Doris A.B., Wahle K., MacDonald A., Morris S., Coffey I., Muir W., Blackwood D. Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. Schizophr. Res. 31:1998;185-196.
10. Easton T., Hirsch S.R., Das I., Kidane L., Richardson A.J., Puri B.K. The relationship of the area under the niacin flush dose-response curve and schizophrenia status. Schizophr. Res. 41:2000;244.
11. Edwards R., Peet M., Shay J., Horrobin D.F. Depletion of docosahexaenoic acid in red blood cell membranes of depressive patients. Biochem. Soc. Trans. 26:1998;S142.
12. Fischer S., Kissling W., Kuss H.J. Schizophrenic patients treated with high dose phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their thrombocytes. Biochem. Pharmacol. 44:1992;317-323.
13. Fox, H., Ross B.M., Tocher D., Horrobin D., Glen I., St. Clair D., in press. Degradation of specific polyunsaturated fatty acids in red blood cells stored at -20°C proceeds faster in patients with schizophrenia compared to healthy controls. Prostaglandins Leukot. Essent. Fat. Acids.
14. Glen A.I., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12:1994;53-61.
15. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukot. Essent. Fat. Acids. 55:1996;9-15.
16. Guy N. ECDEU Assessment Manual for Psychopharmacology. 1976;U.S. Department of Health, Education and Welfare, Washington.
17. Holman R.T., Johnson S. Changes in essential fatty acid profile of serum phospholipids in human disease. Prog. Lipid Res. 20:1981;67-73.
18. Horrobin D.F., Manku M.S., Morse Fisher N., Vaddadi K.S., Courtney P., Glen A.I., Glen E., Spellman M., Bates C. Essential fatty acids in plasma phospholipids in schizophrenics. Biol. Psychiatry. 25:1989;562-568.
19. Horrobin D.F., Manku M.S., Hillman H., Glen I.A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 30:1991;795-805.
20. Hudson C.J., Lin A., Cogan S., Cashman F., Warsh J.J. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia? Biol. Psychiatry. 41:1997;507-513.
21. Kaiya H., Horrobin D.F., Manku M.S., Fisher N.M. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol. Psychiatry. 30:1991;357-362.
22. Kane J.M., Jeste D.V., Barnes T.E. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. 1992;265-268 APA, Washington, DC.
23. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
24. Maes M., Christophe A., Delanghe J., Altamura C., Neels H., Meltzer H.Y. Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res. 85:1999;275-291.
25. Mahadik S.P., Mukherjee S., Horrobin D.F., Jenkins K., Correnti E.E., Scheffer R.E. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 63:1996;133-142.
26. Manku M.S., Horrobin D.F., Huang Y.S., Morse N. Fatty acids in plasma and red cell membranes in normal humans. Lipids. 18:1983;906-908.
27. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98:1992;812-815.
28. Obi F.O., Nwanze E.A. Fatty acid profiles in mental disease: part 1. Linolenate variations in schizophrenia. J. Neurol. Sci. 43:1979;447-454.
29. Overall J.E., Gorham D. The brief psychiatric rating scale. Psychol. Rep. 1962;799-812.
30. Peet M., Laugharne J., Rangarajan N., Horrobin D.F., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29:1995;227-232.
31. Peet M., Murphy B., Shay J., Horrobin D.F. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry. 43:1998;315-319.
32. Puri B.K., Richardson A.J., Easton T. Association of niacin flush response with schizophrenic symptoms. Schizophr. Res. 41:2000;251.
33. Puri B.K., Hirsch S.R., Easton T., Richardson A.J. A volumetric biochemical niacin-flush based index that non-invasively detects fatty acid deficiency in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2001;49-52.
34. Shah S.H., Vankar G.K., Peet M., Ramchand C.N. Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin. Schizophr. Res. 43:2000;163-164.
35. Vaddadi K.S., Gilleard C.J., Mindham R.H., Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology (Berlin). 88:1986;362-367.
36. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 27:1989;313-323.
37. Vaddadi K.S., Gilleard C.J., Soosai E., Polonowita A.K., Gibson R.A., Burrows G.D. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr. Res. 20:1996;287-294.
38. Waldo M.C. Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophr. Res. 40:1999;49-53.
39. Ward P.E., Sutherland J., Glen E.M., Glen A.I. Niacin skin flush in schizophrenia: a preliminary report. Schizophr. Res. 29:1998;269-274.
40. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia: II. Fatty acid composition. Schizophr. Res. 13:1994;217-226.
41. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42:2000;7-17.
42. Young R.C., Biggs J.T., Ziegler V.E., Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry. 133:1978;429-435.